Technical Data
S0098-08
SARS M Protein (Severe Acute Respiratory Syndrome)
Description:
A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome) (1-2). Coronaviruses are a major cause of upper respiratory diseases in humans (3). The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. The M protein (Membrane protein, Matrix protein) is one of the major structural viral proteins. It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein and the nucleocapsid protein (4-5).

Applications:
Can be used for the detection of SARS M protein in ELISA. It will detect 10 ng of free peptide at 1 mg/ml.

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and add glycerol (40-50%). Store at -20C or colder. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
PabIgGAffinity Purified
SizeStorageShippingSourceHost
100ug-20CBlue IceRabbit
Concentration:
~0.5mg/ml
Immunogen:
Raised against a synthetic peptide corresponding to amino acids at the amino-terminus of the SARS M protein (Genbank accession no. P59596)
Purity:
Purified by immunoaffinity chromatography.
Form
Supplied as a liquid in PBS, pH 7.4, 0.02% sodium azide.
Specificity:
Recognizes SARS M protein.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Marra MA, Jones SJ, Astell CR, et al. The Genome sequence of the SARS-associated corona virus. Science 2003;300:1399-404. 2. Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003;300:1394-9. 3. Navas-Nartin SR and Weiss S. Coronavirus replication and pathogenesis: Implications for the recent outbreak of severe acute respiratory syndrome (SARS), and the challenge for vaccine development. J Neurovirol. 2004;10:75-85. 4. Opstelten DJ, Raamsman MJ, Wolfs K, et al. Envelope glycoprotein interactions in coronavirus assembly. J Cell Biol. 1995;131:339-49. 5. Naraytanan K, Maeda A, Maeda J, and Makino S. Characteization of the coronavirus M protein and nucleocapsid interaction in infected cells. J Virol. 2000;74:8127-34.